Differential Competitive Resistance to Methylating Versus Chloroethylating Agents Among Five O6-Alkylguanine DNA Alkyltransferases in Human Hematopoietic Cells

Total Page:16

File Type:pdf, Size:1020Kb

Differential Competitive Resistance to Methylating Versus Chloroethylating Agents Among Five O6-Alkylguanine DNA Alkyltransferases in Human Hematopoietic Cells 121 Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells Aparecida Maria Fontes,1 Brian M. Davis,1 G160S, L162V), MGMT-3 (C150Y, A154G, Y158F, Lance P. Encell,2 Karen Lingas,1 L162P, K165R), and MGMT-5 (N157T, Y158H, A170S; 3 3 M Dimas Tadeu Covas, Marco Antonio Zago, ED50 for benzylguanine, >1,000 mol/L)] were mixed, Lawrence A. Loeb,4 Anthony E. Pegg,5 and the virus produced from Phoenix cells was transduced and Stanton L. Gerson1 into K562 cells. Stringent selection used high doses of O6-benzylguanine (800 Mmol/L) and temozolomide (1,000 1Division of Hematology/Oncology and Comprehensive Cancer Mmol/L) or BCNU (20 Mmol/L) administered twice, and Center, Case Western Reserve University and University Hospitals following regrowth, surviving clones were isolated, and 2 of Cleveland, Cleveland, Ohio; Promega Corporation, Madison, the MGMT transgene was sequenced. None of the Wisconsin; 3Regional Blood Center and Faculdade de Medicina de Ribeira˜o Preto da Universidad de Sa˜o Paulo, Centro de Terapia mutants was lost during selection. Using temozolomide, Celular, Ribeira˜o Preto, Brazil; 4The Joseph Gottstein Memorial the enrichment factor was greatest for P140K-MGMT Cancer Research Laboratory, Department of Pathology, University (1.7-fold). Using BCNU selection, the greatest enrichment of Washington School of Medicine, Seattle, Washington; and was observed with MGMT-2 (1.5-fold). G156A-MGMT, 5 Department of Cellular and Molecular Physiology, Penn State which is the least O6-benzylguanine–resistant MGMT Medical Center, Hershey, Pennsylvania gene of the mutants tested, was not lost during selection but was selected against. The optimal mutant MGMT Abstract useful as a drug resistance gene may depend on whether P140K-MGMT and G156A-MGMT genes encode two a methylating or chloroethylating agent is used for drug O6-benzylguanine–resistant O6-alkylguanine DNA alkyl- selection. [Mol Cancer Ther 2006;5(1):121–8] transferase proteins that confer a high degree of O6- benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea Introduction 6 (BCNU) or O -benzylguanine and temozolomide resistance 6 O -benzylguanine, an inhibitor of the DNA repair protein, to primary hematopoietic cells. In this study, we directly 6 6 O -alkylguanine DNA alkyltransferase (AGT) plus 1,3-bis compared these and three other O -benzylguanine– 6 (2-chloroethyl)-1-nitrosourea (BCNU) or O -benzylguanine resistant MGMT genes for their ability to protect the plus temozolomide have increased therapeutic efficacy over human erythroleukemia cell line, K562, using a direct thechemotherapeuticagentsaloneinanimaltumorxenograft competitive selection strategy to identify the mutation models (1–8). Thus, these combinations are currently being that conferred the greatest degree of protection from O6- evaluated in clinical trials with cutaneous lymphomas, benzylguanine and either BCNU or temozolomide. MFG malignant melanoma, brain neoplasms, multiple myeloma, retroviral vector plasmids for each of these mutants and gastrointestinal carcinomas (9–12). However, the dam- [G156A-MGMT (ED for O6-benzylguanine, 60 Mmol/L); 50 age caused to the bone marrow by these alkylating agents and P140K-MGMT, MGMT-2 (S152H, A154G, Y158H, manifests in the short term as myelosuppression or pancyto- penia, the dose-limiting toxicity in clinical trials, and has the potential to induce therapy-related myelodysplasia or acute leukemia (13, 14). Received 7/11/05; revised 10/7/05; accepted 10/28/05. Mutations in human MGMT have been developed, which Grant support: USPHS grants RO1CA73062, RO1ES06288, retain AGT activity but are O6-benzylguanine resistant. UO1CA75525, and P30CA43703. Based on the crystal structure of the AGT active site pocket, The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked it is apparent that these mutants affect the size, hydropho- advertisement in accordance with 18 U.S.C. Section 1734 solely to bicity, and flexion of the active site pocket, resulting in indicate this fact. exclusion of the benzyl moiety from the active site or a Note: A.M. Fontes is currently at the Regional Blood Center of Ribeira˜o Preto, Ribeira˜o Preto, SP, 14051-140 Brazil. B. Davis is currently at reduction in its ability to undergo an alkyl transfer reaction Virexis, Gaithersburg, Maryland. L. Encell is currently at Tanox, Inc., with the active site cysteine. G156A-MGMT, located within Department of Molecular Biology, 10301 Stella Link, Houston, TX 77025. the DNA-binding wing flanking the alkyl-binding pocket Requests for reprints: Stanton L. Gerson, Division of Hematology 6 (15), is moderately O -benzylguanine resistant (EC50 =60 Oncology, BEB-3 Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-4955. Phone: 216-368-1177; Fax: 216-368-1166. Amol/L). It distorts the adjacent loop (residues 158–160) E-mail: [email protected] that constitutes one wall of the benzyl-binding pocket Copyright C 2006 American Association for Cancer Research. (16, 17). The P140K-MGMT mutant alters the floor of doi:10.1158/1535-7163.MCT-05-0236 the alkyl-binding pocket, excluding the benzyl group and Mol Cancer Ther 2006;5(1). January 2006 Downloaded from mct.aacrjournals.org on September 30, 2021. © 2006 American Association for Cancer Research. 122 O6-Alkylguanine DNA Alkyltransferases resulting in a very high degree of O6-benzylguanine anti-MGMT (monoclonal antibody clone MT3.1) was resistance (EC50 > 1.2 mmol/L; refs. 18, 19). Molecular purchased from Kamiya Biomedical Co. (Seattle, WA), evolution with selection allowed the identification of mul- and R-phycoerythrin–conjugated antibodies were pur- tiple MGMT mutants highly resistant to O6-benzylguanine, chased from Caltag Laboratories (Burlingame, CA). The which retain the AGT ability to remove alkyl adducts from mouse isotype IgG1 was purchased from Becton Dickinson the O6-guanine position in DNA (20). Three mutants (i.e., (San Jose, CA). MGMT-2, MGMT-3, and MGMT-5), each containing three Retroviral Vectors to five amino acid substitutions in the region of the active Retroviral vector pMFG-G156A was constructed to site, were the most resistant to O6-benzylguanine and express cDNA sequence for G156A-MGMT as previously BCNU (EC50 > 2 mmol/L; ref. 20). described (15). Retroviral vector pMFG-P140K was con- These mutants, O 6-benzylguanine–resistant MGMT structed to express cDNA sequence for P140K-MGMT genes, provide a potent selection strategy for drug resistance by Davis et al. (22) and was originally selected for gene transfer. We have used this for hematopoietic stem dual resistance to N-methyl-NV-nitro-N-nitrosoguanidine cell selection because two chemotherapeutic agents, BCNU, and O6-benzylguanine from a library of AGT mutants and methylating agents, such as temozolomide, are stem cell containing a random sequence at positions 138 to 140 (18). toxins, resulting in cumulative stem cell loss and delayed Retroviral vectors pMFG-MGMT-2, pMFG-MGMT-3, and myelosuppression. We first introduced the use of O6- pMFG-MGMT-5, containing the following mutations of benzylguanine–resistant G156A-MGMT to selectively pro- the MGMT gene,aspreviouslydescribed,MGMT-2 tect the human CD34 cells and suggested that this selective (S152H, A154G, Y158H, G160S, L162V), MGMT-3 (C150Y, protection could occur while sensitizing the tumor to A154G, Y158F, L162P, K165R), and MGMT-5 (N157T, chemotherapy using O6-benzylguanine (21). Selecting the Y158H, A170S), were subcloned into MFG retroviral vector best O6-benzylguanine–resistant MGMT for gene therapy (20). These three MGMT mutant genes were originally is an important therapeutic decision. These mutants selected for dual resistance to N-methyl-NV-nitro-N-nitro- vary in stability, level of O6-benzylguanine resistance, soguanidine and O6-benzylguanine from a library of MGMT and repair capacity for either O6-methylguanine or O6- mutant genes containing a random sequence at positions 150 chloroethylguanine. The aim of the present study was to to 172 (19) and conferred the greatest degree of resistance to compare the ability of five of the most potent MGMT O6-benzylguanine and BCNU in K562 cells (20). mutants to protect human hematopoietic cells against CellTransfections and Transductions toxicity from O6-benzylguanine + BCNU or O6-benzylgua- DNA from each retroviral vector plasmid was isolated nine + temozolomide treatment using a direct competitive using NucleoBond Plasmid Max kit from Clontech selection strategy. (Palo Alto, CA) and then pooled by mixing 2 Ag of each construct. A total of 10 Agofretroviralplasmidwas transfected into 5 Â 106 Phoenix amphotropic packaging Materials and Methods cells (a gift from G. Nolon, Stanford University, Stanford, Chemicals CA), using a calcium phosphate coprecipitation protocol.4 BCNU and temozolomide were obtained from the To transduce K562 cells, these amphotropic producer cells Developmental Therapeutics Branch, National Cancer were grown to confluence, and the virus was harvested in Institute (Bethesda, MD). The BCNU was solubilized DMEM supplemented with 10% heat-inactivated fetal in 100% ethanol before dilution in PBS and used within bovine serum. To remove contaminating producer cells, 10 minutes of reconstitution. Temozolomide was solubi- supernatant was filtered through a 0.45-Am filter (Millipore, lized in DMSO (Sigma, St. Louis, MO) before dilution in Bedford, MA). Polybrene was added at 5.5
Recommended publications
  • National Institute of Science and Tecnology in Stem Cells and Cell Therapy in Cancer
    1 National Institutes of Science and Tecnology Edital N. 16/2014 MCTI/CNPq/ /CAPES/FAPs National Institute of Science and Tecnology in Stem Cells and Cell Therapy in Cancer INCTC Coordinator: Dimas Tadeu Covas Vice-Coordinator: Eduardo Magalhães Rego Headquarters: Hemocentro Foundation and Ribeirão Preto Medical School 2 SUMMARY A) Headquarters 4 B) Institutions, Laboratories and Associated Research Groups 4 C) Management Committee 4 D) Principal Investigators 5 D.1) Detailed description oF the proposing group 5 D.2) International Collaborators 14 D.3) Associated Researchers 14 D.4) Technical Team and post-graduate students associated with the project 15 D.5) ) Technical Team and post-graduate students associated with PIs 16 E) Organization and Functional Chart oF the Institute 17 F) Mechanisms that will be used to promote the interaction among groups and Forms 18 of interaction with groups abroad G) SpeciFication of the activities to be developed by team members 20 H) DeFinition of specific tasks of every participant entity 22 I) Description of the Program of the Institute 22 J) Detailing the Research Program 30 J.1) Description of the scientiFic project 31 J.2) Subprojects, objectives and goals 49 J.3) Methodology 62 J.4) Follow-up Indicators of the project 66 K) Detailing the program oF qualiFied proFessional training 67 L) Detailing the actions oF knowledge transFer to society 69 M) Detailing the actions oF knowledge transFer to business sector or Formulation oF 72 public policies N) Potential For generating patents 75 O) ScientiFic
    [Show full text]
  • Relatório Anual De 2016
    2016 Report FFM - 2016 Annual Report 1 / 147 FFM - 2016 Annual Report 2 / 147 SUMMARY 05 PRESENTATION 07 MESSAGE FROM THE BOARD OF DIRECTORS 13 FFM IN NUMBERS 15 INTEGRAL HEALTH CARE ACTIONS 16 FM/HCFMUSP SYSTEM 19 USP SCHOOL OF MEDICINE 21 HOSPITAL DAS CLÍNICAS DA FMUSP (CLINICS HOSPITAL OF THE UNIVERSITY OF SÃO PAULO SCHOOL OF MEDICINE) 23 UNIVERSITY AGREEMENT 27 Special Procedures 30 Institutes, Auxiliary Hospitals and Specialized Health Units from HCFMUSP System 43 Other Health Units 45 MANAGEMENT CONTRACTS 45 Lucy Montoro Rehabilitation Institute Management Contract 48 City Management Contract of the West Region Project 49 City Management Contract of the Pronto-Socorro do Butauntã (Emergency Room) 50 ICESP MANAGEMENT AGREEMENT 55 SOCIAL AID ACTIONS 56 MAJOR SOCIAL AID PROJECTS 56 "Bandeira Científica" Project 58 Equilíbrio Program 58 Mental Health Training - CASA Foundation 60 "Visão do Futuro" (Vision Of Future) Program 61 Treatment of Cleft Palate 61 AFINAL Program 62 Family Health Program FFM - 2016 Annual Report 3 / 147 63 AID PROJECTS 64 HIV/AIDS VIRUS AND SEXUALLY TRANSMITTED DISEASES CARRIERS 70 PEOPLE WITH DISABILITY 73 ONCOLOGICAL PATIENTS 79 CHILDREN AND YOUTH 84 FAMILIES AND WOMEN 86 ELDERLY 91 RESEARCH PROJECT 92 MAIN RESEARCH PROJECTS 104 CLINICAL STUDIES 107 HEALTH POLICY PROJECTS 108 MAIN HEALTH POLICY PROJECTS 119 INSTITUTIONAL PROJECTS 120 MAIN INSTITUTIONAL PROJECTS 127 FFM PROFILE 128 BRIEF HISTORY 129 CONSOLIDATED RESULTS 130 STRATEGIES 135 ORGANIZATIONAL STRUCTURE 141 2016 FINANCIAL BALANCE SHEET SUMMARY 143 ABBREVIATIONS USED IN THIS REPORT 146 FFM ADMINISTRATION 147 EDITORIAL BOARD AND STAFF FFM - 2016 Annual Report 4 / 147 PRESENTATION As an institution that supports the growth and excellence initiatives achieved by the FM/HCFMUSP System year after year, FFM presents its activity report with the results obtained in 2016, in all its instances of operation.
    [Show full text]
  • Manual De Diagnóstico E Tratamento De Doenças Falciformes
    2 Manual de Diagnóstico e Tratamento de Doenças Falciformes Agência Nacional de Vigilância Sanitária Manual de Diagnóstico e Tratamento de Doenças Falciformes Brasília - 2002 Direitos reservados da Agência Nacional de Vigilância Sanitária SEPN 515, Edifício Ômega, Bloco B, Brasília (DF), CEP 707770-502 Internet: www.anvisa.gov.br E-mail:[email protected] É permitida a reprodução desde que citada a fonte. Copyright 2002. Agência Nacional de Vigilância Sanitária (ANVISA) 1º Edição 2002 Agência Nacional de Vigilância Sanitária Design Gráfico e Ilustrações: Gerência de Comunicação Multimídia Divulgação: Unidade de Divulgação Impresso no Brasil Manual de Diagnóstico e Tratamento de Doença Falciformes. - Brasília : ANVISA, 2001. 142p. ISBN 85-88233-04-5 WH155 1. Anemia Falciforme. 2. Doença Falciforme. 3. Doenças Sanguíneas e Linfáticas. I. Brasil. Agência Nacional de Vigilância Sanitária. APRESENTAÇÃO É com muita satisfação que estamos disponibilizando este Manual aos profissionais da saúde que atuam, principalmente, nas áreas de Pediatria, Clínica Médica e Hematologia. Este trabalho é fruto da enorme colaboração do Grupo de Hemoglobinopatias, que vem assessorando a Gerência-Geral de Sangue, outros Tecidos e Órgãos - GGSTO na implementação da Política de Assistência aos Portadores de Hemoglobinopatias, liderado pela Dra. Terezinha Saad da UNICAMP. Esperamos que esta publicação possa ajudar aos profissionais na atenção dispensada aos pacientes, transmitindo as informações necessárias de forma objetiva e clara, visando as melhoria da assistência médica, especificamente dos portadores da Anemia Falciforme. Dra. Beatriz Mac-Dowell Soares Gerente Geral de Sangue, outros Tecidos e Órgãos GGSTO/ANVISA/MS 6 Manual de Diagnóstico e Tratamento de Doenças Falciformes SUMÁRIO CONSIDERAÇÕES GERAIS ......................................................................................07 Marco Antonio Zago FISIOPATOLOGIA DAS DOENÇAS FALCIFORMES ...............................................13 Sandra F.
    [Show full text]
  • Universidade De São Paulo Faculdade De Odontologia De Bauru
    UNIVERSIDADE DE SÃO PAULO FACULDADE DE ODONTOLOGIA DE BAURU CLAUDIA CRISTINA BIGUETTI Role of DAMPS on the modulation of macrophage response after classical biomaterial (Ti) implantation and its impact on the subsequent repair and osseointegration processes Participação de DAMPs na modulação da resposta de macrófagos à implantação de um biomaterial clássico (Ti) e seu impacto no processo de reparo e osseointegração subsequentes BAURU 2018 CLAUDIA CRISTINA BIGUETTI Role of DAMPS in the modulation of macrophage response after classical biomaterial (Ti) implantation and its impact in the subsequent repair and osseointegration processes. Participação de DAMPs na modulação da resposta de macrófagos à implantação de um biomaterial clássico (Ti) e seu impacto no processo de reparo e osseointegração subsequentes Tese constituída por artigos apresentada a Faculdade de Odontologia de Bauru da Universidade de São Paulo para obtenção do título de Doutor em Ciências no Programa de Ciências Odontológicas Aplicadas, na área de concentração Biologia Oral. Orientador: Prof. Dr. Gustavo Pompermaier Garlet BAURU 2018 Biguetti, Claudia Cristina B488r Role of DAMPS on the modulation of macrophage response after classical biomaterial (Ti) implantation and its impact in the subsequent repair and osseointegration processes. / Claudia Cristina Biguetti. – Bauru, 2018. 135 p. : il. ; 30 cm. Tese (Doutorado) – Faculdade de Odontologia de Bauru. Universidade de São Paulo Orientador: Prof. Dr. Gustavo Pompermaier Garlet Autorizo, exclusivamente para fins acadêmicos e científicos, a reprodução total ou parcial desta tese, por processos fotocopiadores e outros meios eletrônicos. Claudia Cristina Biguetti Data: DEDICATÓRIA Dedico este trabalho aos meus pais, Izildinha Rodrigues e Luiz Biguetti AGRADECIMENTOS Ao meu orientador Prof. Dr. Gustavo Pompermaier Garle t.
    [Show full text]
  • Revista Brasileira De Ciências Farmacêuticas Brazilian Journal of Pharmaceutical Sciences
    Volume 41, supl. 1, 2005 ISSN 1516-9332 Revista Brasileira de Ciências Farmacêuticas Brazilian Journal of Pharmaceutical Sciences 5th INTERNATIONAL CONGRESS OF PHARMACEUTICAL SCIENCES CIFARP 2005 Ribeirão Preto - São Paulo - Brasil September 25 - 28, 2005 Faculdade de Ciências Farmacêuticas Universidade de São Paulo evista Brasileira de Ciências Farmacêuticas/ Brazilian JournalR of Pharmaceutical Sciences, editada pela Faculdade de Ciências Farmacêuticas da Universidade de São Paulo, com Revista Brasileira de periodicidade trimestral, vem dar continuidade à “Revista de Farmácia e Bioquímica da Universidade de São Paulo”, cuja origem remonta aos “Anais de Farmácia e Odontologia da USP”, Ciências Farmacêuticas iniciada em 1939. The Revista Brasileira de Ciências Farmacêuticas/ Brazilian Journal of Pharmaceutical Sciences is edited quarterly by the Assinatura/Subscription College of Pharmaceutical Sciences, University of São Paulo Brazil Outside Brazil and was formerly known as the “Revista da Faculdade de Instituição/Institution R$ 260,00 US$ 80,00 Farmácia e Bioquímica da Universidade de São Paulo”, which has its origin in the “Anais de Farmácia e Odontologia da USP”, Individual/Private R$ 130,00 US$ 40,00 wich began in 1939. Doação/Gift Serviços de Informação/Information Services Somente para instituições públicas de ensino e pesquisa. A Revista Brasileira de Ciências Farmacêuticas/Brazilian Journal of Pharmaceutical Sciences é indexada nas seguintes Only to public teaching and research organizations. bibliografias: Analytical Abstracts, Chemical Abstracts, Excerpta Médica, International Pharmaceutical Abstracts, LILACS e Permuta/Exchange Nutrition Abstracts and Reviews. Com títulos de periódicos que sejam de interesse para o A Revista Brasileira de Ciências Farmacêuticas/ Brazilian Journal of Pharmaceutical Sciences is covered by the following acervo da Divisão de Biblioteca e Documentação bibliographies: Analytical Abstracts, Chemical Abstracts, Excerpta do Conjunto das Químicas.
    [Show full text]
  • Franco-Brazilian Collaboration in Hematology International Research Network on Hematology (IRNH)
    Franco-Brazilian collaboration in Hematology International Research Network on Hematology (IRNH) New emerging collaboration The genesis of a project: from the late 90s Analysis of the 677C→T mutation of the Methylenetetrahydrofolate Reductase Gene in Different Ethnic Groups R. F. Franco, A. G. Araújo, J. F. Guerreiro, J. Elion, M. A. Zago Thromb Haemost. 1998 Jan;79(1):119-21. The phylogeography of mitochondrial DNA haplogroup L3g in Africa and the Atlantic slave trade. Bortoloni MC, Da Silva WA Jr, Zago MA, Elion J, Krishnamoorthy R, Goncalves VF, Pena SD Am. J. Hum. Genet. 75:523–524, 2004 from population genetics… ….to cellular and molecular hematology Cellular and Molecular Effects of Hydroxycarbamide in Sickle Cell Patients Silva-Pinto AC, de Cássia Viu Carrara R, V.B. Palma P, Zago MA, Elion J, Covas DT Current Pharmacogenomics and Personalized Medicine, 2014, 12, 114-122 15 publications 1998-2015 The genesis of a project (II): from the early 2000s clinical hematology Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation Vanderson Rocha, Rendrik F. Franco, Raphael Porcher, Henrique Bittencourt, Wilson A. Silva Jr, Aurelien Latouche, Agnes Devergie, Helene Esperou, Patricia Ribaud, Gerard Socie, Marco Antonio Zago, and Eliane Gluckman Blood. 2002 Dec 1;100(12):3908-18 Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation. Peffault de Latour R, Calado RT, Busson M, Abrams J, Adoui N, Robin M, Larghero J, Dhedin N, Xhaard A, Clave E, Charron D, Toubert A, Loiseau P, Socié G, Young NS.
    [Show full text]
  • Annual Report Fapesp Report Annual 2019
    ANNUAL REPORT FAPESP www.fapesp.br/en ANNUAL REPORT REPORT ANNUAL FAPESP 2019 FAPESP 2019 SÃO PAULO RESEARCH FOUNDATION Rua Pio XI, 1500 – Alto da Lapa CEP 05468-901 – São Paulo, SP SÃO PAULO RESEARCH FOUNDATION Secretaria de Desenvolvimento Econômico Secretaria de Desenvolvimento Econômico ANNUAL REPORT FAPESP 2019 SÃO PAULO RESEARCH FOUNDATION FAPESP 2019 YEAR 2019 YEAR 2020 SÃO PAULO STATE GOVERNOR SÃO PAULO STATE GOVERNOR João Doria João Doria SECRETARY OF ECONOMIC DEVELOPMENT, SCIENCE SECRETARY OF ECONOMIC DEVELOPMENT, SCIENCE AND TECHNOLOGY AND TECHNOLOGY Patricia Ellen da Silva Patricia Ellen da Silva SÃO PAULO RESEARCH FOUNDATION SÃO PAULO RESEARCH FOUNDATION PRESIDENT PRESIDENT Marco Antonio Zago Marco Antonio Zago VICE PRESIDENT VICE PRESIDENT Eduardo Moacyr Krieger (until August 29th) Ronaldo Aloise Pilli Ronaldo Aloise Pilli (since October 11thx) BOARD OF TRUSTEES BOARD OF TRUSTEES Carmino Antonio de Souza Carmino Antonio de Souza Helena Nader (since February 5th) Eduardo Moacyr Krieger (until August 29th) Ignácio Maria Poveda Velasco Ignácio Maria Poveda Velasco João Fernando Gomes de Oliveira João Fernando Gomes de Oliveira Liedi Legi Bariani Bernucci José de Souza Martins (until August 29th) Marco Antonio Zago Liedi Legi Bariani Bernucci Mayana Zatz Marco Antonio Zago Mozart Neves Ramos Marilza Vieira Cunha Rudge (until December, 11th) Pedro Luiz Barreiros Passos Mayana Zatz (since August 31th) Pedro Wongtschowski Mozart Neves Ramos (since August 31th) Ronaldo Aloise Pilli Pedro Luiz Barreiros Passos Vanderlan da Silva
    [Show full text]
  • Programa Oficial Official Program
    PROGRAMA OFICIAL OFFICIAL PROGRAM www.hemo.org.br ÍNDICE/INDEX pág./page MENSAGEM DO PRESIDENTE DO CONGRESSO/ MESSAGE OF THE CONGRESS PRESIDENT ........................................................... 5 ONDE ACONTECE/EVENT VENUE ........................................................................ 6 ABERTURA OFICIAL/OFFICIAL OPENING .............................................................. 7 EVENTOS MULTIDISCIPLINARES/MULTIDISCIPLINARY EVENTS ........................... 7 COMISSÕES/COMMITTEES .................................................................................. 8 HOMENAGENS/HONORS ..................................................................................... 9 CONVIDADOS INTERNACIONAIS/INTERNATIONAL GUESTS ................................ 10 CONVIDADOS NACIONAIS/NATIONAL GUESTS .................................................... 20 UMA BATALHA DE CONHECIMENTO ESPERA POR VOCÊ INFORMAÇÕES GERAIS/GENERAL INFORMATION ............................................... 22 PLANTAS/FLOOR PLAN ........................................................................................ 28 EXPOSITORES HEMO 2014/HEMO 2014 EXHIBITORS ........................................... 30 SIMPÓSIO SUPERQUINTA CRONOGRAMA/SCHEDULE ................................................................................. “Controvérsias na Leucemia Linfocítica Crônica” 32 - O grande debate PROGRAMAÇÃO CIENTÍFICA/SCIENTIFIC PROGRAM O tratamento da LLC apresentou uma grande evolução • PROGRAMA EDUCACIONAL/EDUCATIONAL PROGRAM na última década, mas
    [Show full text]
  • Relatório Anual De 2001
    2017 Activities Report . FFM − 2017 Annual Report 1 / 136 FFM − 2017 Annual Report 2 / 136 SUMMARY 05 PRESENTATION 07 MESSAGE FROM THE BOARD OF DIRECTORS 08 FFM IN NUMBERS 09 INTEGRAL HEALTH CARE ACTIONS 10 FM/HCFMUSP SYSTEM 13 USP SCHOOL OF MEDICINE 15 HOSPITAL DAS CLÍNICAS DA FMUSP (CLINICS HOSPITAL OF THE UNIVERSITY OF SÃO PAULO SCHOOL OF MEDICINE) 17 UNIVERSITY AGREEMENT 21 Special Procedures 24 Institutes, Auxiliary Hospitals and Specialized Health Units from HCFMUSP System 37 Other Health Units 39 MANAGEMENT CONTRACTS 39 Management Contract of the Cancer Institute of the State of São Paulo − ICESP 43 Lucy Montoro Rehabilitation Institute Management Contract 47 SOCIAL AID ACTIONS 48 MAJOR SOCIAL AID PROJECTS 48 "Bandeira Científica" Project 50 Equilíbrio Program 51 "Visão do Futuro" (Vision of Future) Program 52 AFINAL Program 53 Treatment of Cleft Palate 53 Mental Health Training − CASA Foundation FFM − 2017 Annual Report 3 / 136 55 AID PROJECTS 56 HIV/AIDS VIRUS AND SEXUALLY TRANSMITTED DISEASES CARRIERS 62 PEOPLE WITH DISABILITY 66 ONCOLOGICAL PATIENTS 73 CHILDREN AND YOUTH 77 FAMILIES AND WOMEN 79 ELDERLY 83 RESEARCH PROJECT 84 MAIN RESEARCH PROJECTS 97 CLINICAL STUDIES 99 HEALTH POLICY PROJECTS 100 MAIN HEALTH POLICY PROJECTS 111 INSTITUTIONAL PROJECTS 112 MAIN INSTITUTIONAL PROJECTS 117 FFM PROFILE 118 BRIEF HISTORY 119 CONSOLIDATED RESULTS 120 STRATEGIES 126 ORGANIZATIONAL STRUCTURE 131 2017 FINANCIAL BALANCE SHEET SUMMARY 133 ABBREVIATIONS USED IN THIS REPORT 135 FFM ADMINISTRATION 136 EDITORIAL BOARD FFM − 2017 Annual Report 4 / 136 PRESENTATION FFM reinforces its commitment in supporting the activities of theFMUSP and its HCFMUSP, by complying with their statute guidelines.
    [Show full text]
  • Hayek and Complexity: Coordination, Evolution and Methodology In
    UNIVERSIDADE DE SÃO PAULO Faculdade de Economia, Administração e Contabilidade Programa de pós-graduação em Economia Hayek and complexity: coordination, evolution and methodology in social adaptive systems Hayek e a complexidade: coordenação, evolução e metodologia em sistemas sociais adaptativos Gabriel Oliva Costa Cunha São Paulo 2016 Prof. Dr. Marco Antonio Zago Reitor da Universidade de São Paulo Prof. Dr. Adalberto Américo Fischmann Diretor da Faculdade de Economia, Administração e Contabilidade Prof. Dr. Hélio Nogueira da Cruz Chefe do Departamento de Economia Prof. Dr. Márcio Issao Nakane Coordenador do Programa de Pós-Graduação em Economia GABRIEL OLIVA COSTA CUNHA Hayek and complexity: coordination, evolution and methodology in social adaptive systems Hayek e a complexidade: coordenação, evolução e metodologia em sistemas sociais adaptativos Dissertação apresentada ao Departamento de Economia da Faculdade de Economia, Administração e Contabilidade da Universidade de São Paulo (FEA-USP) como requisito parcial para a obtenção do título de Mestre em Ciências. Orientador: Prof. Dr. Jorge Eduardo de Castro Soromenho Versão Corrigida (versão original disponível na Biblioteca da Faculdade de Economia, Administração e Contabilidade) São Paulo 2016 FICHA CATALOGRÁFICA Elaborada pela Seção de Processamento Técnico do SBD/FEA/USP Cunha, Gabriel Oliva Costa Hayek and complexity: coordination, evolution and methodology in social adaptive systems / Gabriel Oliva Costa Cunha. – São Paulo, 2016. 115 p. Dissertação (Mestrado) – Universidade de São Paulo, 2016. Orientador: Jorge Eduardo de Castro Soromenho. 1. Economia 2. Complexidade 3. Hayek, F.A. 4. Teoria geral do sistema I. Universidade de São Paulo. Faculdade de Economia, Administração e Contabilidade. II. Título. CDD – 330 Resumo A afinidade entre a obra do economista austríaco Friedrich A.
    [Show full text]
  • Origin of the Hemoglobin S Gene in a Northern Brazilian Population: the Combined Effects of Slave Trade and Internal Migrations
    Origin of the hemoglobin S gene in a northern Brazilian population: the combined effects of slave trade and internal migrations Gabriella Pante-de-Sousa1, Rita de Cassia Mousinho-Ribeiro1, Eduardo José Melo dos Santos1, Marco Antonio Zago2 and João Farias Guerreiro1 1Laboratório de Genética Humana e Médica, Departamento de Patologia, Centro de Ciências Biológicas, Universidade Federal do Pará, Caixa Postal 8615, 66075-900 Belém, PA, Brasil. Send correspondence to J.F.G. 2Departamento de Clinica Médica, Faculdade de Medicina, Universidade de São Paulo,14049-900 Ribeirão Preto, SP, Brasil. ABSTRACT We analyzed DNA polymorphisms in the -globin gene cluster of 30 sickle cell anemia patients from Belém, the capital city of the State of Pará, in order to investigate the origin of the S mutation. Sixty-seven percent of the S chromosomes were Bantu type, 30% were Benin type, and 3% were Senegal type. The origin of the S mutation in this population, estimated on the basis of bS-linked haplotypes, contradicts the historical records of direct slave trade from Africa to the northern region of Brazil. Historical records indicate a lower percentage of people from Benin. These discrepancies are probably due to domestic slave trade and later internal migrations, mainly from northeastern to northern regions. Haplotype distribution in Belém did not differ significantly from that observed in other Brazilian regions, although historical records indicate that most slaves from Atlantic West Africa, where the Senegal haplotype is prevalent, were destined for the northern region, whereas the northeast (Bahia, Pernambuco and Maranhão) was heavily supplied with slaves from Central West Africa, where the Benin haplotype predominates.
    [Show full text]
  • Annual Report 2014 2/127
    Annual Report 2014 Summary INTRODUCTION 04 THE SCHOOL OF MEDICINE FOUNDATION AND ITS MANAGEMENT MODEL 06 FFM SOCIAL REACH IN FIGURES 08 1 INTEGRAL HEALTH ASSISTANCE ACTION 09 1.1 FM/HCFMUSP SYSTEM 10 1.2 UNIVERSITY AGREEMENT 12 1.2.1 Special Procedures 16 1.2.2 FM/HCFMUSP System Institutes, Auxiliary Hospitals and Specialized Health Units 19 1.2.3 Other Health Units 32 1.3 MANAGEMENT AGREEMENTS 35 1.3.1 West Region Project Municipal Administration Agreement ‐ PRO 35 1.3.2 Butantã Emergency Room Municipal Management Agreement 37 1.3.3 Lucy Montoro Institute State Management Agreement ‐ IRLM 38 1.4 ICESP AGREEMENT 41 2 SOCIAL ASSISTANCE ACTIONS 45 2.1 MAIN SOCIAL ASSISTANCE PROJECTS 46 2.1.1 Programa Equilíbrio (Balance Program) 46 2.1.2 Mental Health Program for Interns – CASA Foundation 48 2.1.3 “Scientist Flag 2014” Project 49 2.1.4 “Vision of Future” Program 50 2.1.5 Student Financial Aid Program‐ AFINAL 51 2.1.6 Preventive Measures in School Projec 52 2.1.7 IRLM Mobile Unit 53 2.1.8 Protocol for Treatment of Patients with Cleft Palate Labiopalatinas 53 2.1.9 Family Health Program – PSF 54 3 KEY CARE PROJECTS 55 3.1 HIV‐AIDS VIRUS AND OTHER SEXUALLY TRANSMITTED DISEASES CARRIERS 56 3.2 PEOPLE WITH DISABILITY 62 3.3 CHILDREN AND YOUTH 66 3.4 FAMILIES AND WOMEN 70 3.5 ELDERLY 71 FFM – Annual Report 2014 2/127 4 RESEARCH PROJECTS 73 4.1 MAIN RESEARCH PROJECTS 74 4.2 CLINICAL STUDIES 84 5 HEALTH POLICIES PROJECTS 86 5.1 MAIN HEALTH POLICIES PROJECTS 87 6 INSTITUCIONAL PROJECTS 98 6.1 MAIN INSTITUCIONAL PROJECTS 99 7 FFM PROFILE 109 7.1 BRIEF HISTORY 110 7.2 FFM CONSOLIDATED RESULTS 111 7.3 ESTRATEGIES 112 7.4 ORGANIZATIONAL STRUCTURE 117 8 FINANCIAL BALANCE SUMMARY 2014 121 FFM ADMINISTRATION 123 ABBREVIATIONS OF THIS REPORT 124 MASTHEAD 126 FFM – Annual Report 2014 3/127 Introduction As an institution that supports growth and excellence the FM/HCFMUSP System has been achieving year after year, FFM presents its activities report with results achieved in the previous year, in all of its operation instances.
    [Show full text]